Haemonetics Corp HAE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if HAE is a good fit for your portfolio.
News
-
Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2025 Results: August 8, 2024
-
Haemonetics Launches Limited Market Release for New VASCADE MVP XL Vascular Closure Device
-
Haemonetics Prices Upsized Private Placement of $600 Million Convertible Senior Notes
-
Haemonetics Announces Proposed Convertible Senior Notes Offering
-
Haemonetics 4th Quarter and Fiscal Year 2024 Earnings Release Available on Investor Relations Website
-
Haemonetics Gets FDA Clearance For Enhancements to NexSys PCS System
Trading Information
- Previous Close Price
- $90.60
- Day Range
- $90.29–92.74
- 52-Week Range
- $70.74–97.97
- Bid/Ask
- $86.40 / $92.00
- Market Cap
- $4.64 Bil
- Volume/Avg
- 296,374 / 593,043
Key Statistics
- Price/Earnings (Normalized)
- 22.88
- Price/Sales
- 3.58
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Stock Style Box
- Small Core
- Total Number of Employees
- 3,657
- Website
- https://www.haemonetics.com
Competitors
Valuation
|
Metric
|
HAE
|
MDT
|
|---|---|---|
Price/Earnings (Normalized) | 22.88 | 15.11 |
Price/Book Value | 4.82 | 2.06 |
Price/Sales | 3.58 | 3.23 |
Price/Cash Flow | 18.25 | 14.40 |
Price/Earnings
HAE
MDT
Financial Strength
|
Metric
|
HAE
|
MDT
|
|---|---|---|
Quick Ratio | 1.28 | 1.31 |
Current Ratio | 2.56 | 2.03 |
Interest Coverage | 12.67 | 7.73 |
Quick Ratio
HAE
MDT
Profitability
|
Metric
|
HAE
|
MDT
|
|---|---|---|
Return on Assets (Normalized) | 9.88% | 7.64% |
Return on Equity (Normalized) | 22.73% | 13.51% |
Return on Invested Capital (Normalized) | 12.64% | 9.78% |
Return on Assets
HAE
MDT
Medical Instruments & Supplies Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Intuitive Surgical Inc
ISRG
| Wzhfwlvqc | Qghnd | $156.8 Bil | |||
| Becton Dickinson & Co
BDX
| Yzdbzkvz | Gfvdyy | $68.6 Bil | |||
| Alcon Inc
ALC
| Gshcvnwv | Lfdxmf | $46.5 Bil | |||
| Coloplast A/S ADR
CLPBY
| Szkhsqhgy | Kjmp | $29.1 Bil | |||
| ResMed Inc
RMD
| Jpzgfkjk | Nctjghd | $28.9 Bil | |||
| West Pharmaceutical Services Inc
WST
| Cbyygszfh | Cvbx | $20.7 Bil | |||
| The Cooper Companies Inc
COO
| Ysxvzgyhg | Gkrgbd | $18.6 Bil | |||
| Hologic Inc
HOLX
| Cwwmbckyz | Lzqndjn | $18.4 Bil | |||
| Baxter International Inc
BAX
| Qwwzywhnh | Bxxtc | $18.1 Bil | |||
| Teleflex Inc
TFX
| Bvrv | Ptj | $10.4 Bil |